Genedata Imagence、Bio-IT World 2019 "Best of Show Award"を受賞
Innovative software solution revolutionizes high-content image analysis workflow using AI approach
April 25, 2019
Genedata, a leading provider of advanced software solutions for biopharmaceutical R&D, today announced it received the 2019 Bio-IT World Conference & Expo Best of Show Award for Genedata Imagence® in the “No BS AI” category. Genedata Imagence is the industry’s first commercial, instrument-independent solution for automated high-content screening (HCS) image analysis at an enterprise scale, which applies a deep-learning approach. Judged by a Bio-IT World panel of experts from academia and industry, Genedata Imagence was recognized for its innovation and ability to “measurably improve workflow or capacity, enabling better research.”
Imagence Drives Research Forward
According to Bio-IT World judges, “imaging is the perfect use case for AI and the one with the most powerful and immediate impact. This new product – Genedata Imagence – is one the judges are excited to watch closely as it empowers biologists to make full use of AI to drive research forward.”
The deep learning-based solution accelerates, by orders of magnitude, the time-consuming and complex process of analyzing phenotypic high-content images. Delivering reproducible, unbiased results proven to be equal to or better than results from more traditional analysis approaches, Genedata Imagence enables biologists to quickly and routinely set up and analyze HCS campaigns without image analysis expertise. Specifically, Genedata Imagence:
- rapidly detects and defines all cellular phenotypes in an HCS assay;
- efficiently generates deep learning training data for subsequent classification of HCS image sets in production assays;
- precisely quantifies the relevant pharmacology; and
- produces quality results from a new experiment in just seconds vs. weeks typically required by manual optimization with existing legacy systems.
“Genedata Imagence is revolutionizing a key process in biopharmaceutical R&D,” said Dr. Othmar Pfannes, CEO of Genedata. “We are honored to have Bio-IT World recognize the impact of this solution for improving the efficiency of data-driven drug discovery and development. Our early-access biopharma partners are already seeing the predicted gains in efficiency and scale-up of high-content screens with Imagence. We are now rolling out Imagence to the industry to advance research in the age of artificial intelligence.”
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.